Dr. Reddy's Laboratories announces the launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).

Dr. Reddy's Regadenoson Injection is supplied as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4936.90 as compared to the previous close of Rs. 4969.60. The total number of shares traded during the day was 4733 in over 979 trades.

The stock hit an intraday high of Rs. 4987.00 and intraday low of 4920.10. The net turnover during the day was Rs. 23442811.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RegadenosonInjection USMarket